Dr. Andrew Levin is a Partner on the Investment Team at RA Capital Management, LP, where he brings deep expertise in life sciences investing to support innovative biopharmaceutical companies. Prior to joining RA Capital in 2015, he was a Vice President at H.I.G. BioVentures and Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. Dr. Levin holds a BS in mechanical engineering from Princeton University, an MD from Harvard Medical School, and a PhD in biomedical engineering from the Massachusetts Institute of Technology.
